Dr. Yanping Mao 毛燕萍
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for head and neck tumors, with a focus on intensity-modulated radiation therapy (IMRT) and comprehensive treatment for nasopharyngeal, hypopharyngeal, and laryngeal cancers.
Dr. Mao is a Chief Physician and Master’s supervisor. Clinical interests include combined radiotherapy and chemotherapy for nasopharyngeal cancer, individualized chemotherapy, IMRT and comprehensive treatment for hypopharyngeal and laryngeal cancers with larynx preservation, and IMRT for head and neck tumors.
Professional roles
- Member, Nasopharyngeal Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, 4th Head and Neck Tumor Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, 2nd Head and Neck Tumor Professional Committee, Guangzhou Anti-Cancer Association (GACA)
- Member, Radiobiology and Immunology Group, 2nd Committee of Radiation Oncology Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Mao Yanping). Papers usually list the name as Yanping Mao or Mao Y.
Selected publications
172 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMJ, 2026 (senior author): Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial. PubMed 41916649
- Cancer Immunol Immunother, 2026 (senior author): PD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study. PubMed 41739217
- Eur Radiol, 2024 (senior author): Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy. PubMed 38514481
- Cell Death Dis, 2024 (senior author): The circadian gene ARNTL2 promotes nasopharyngeal carcinoma invasiveness and metastasis through suppressing AMOTL2-LATS-YAP pathway. PubMed 38956029
- Radiother Oncol, 2023 (senior author): Clinical characteristics, prognostic factors, and treatment modalities for head and neck lymphoepithelioma-like carcinoma: A real-world study from southern China. PubMed 37480992
- BMJ, 2023 (first author): Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. PubMed 36746459
- Front Immunol, 2022 (senior author): Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. PubMed 35140722
- Exp Biol Med (Maywood), 2021 (senior author): Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7. PubMed 34424090
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion